Case ReportCase Report

Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report

Ling Zhang, Yunxia Li, Shaohong Zhang, Chen Gao, Keke Nie and Youxin Ji
Cancer Biology & Medicine May 2018, 15 (2) 178-181; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0003

Article Figures & Data

Figures

  • 1
    1

    (A) A CAT scan showed a 2.5 × 2.5 cm, round node on the left upper lung and an irregular mediastinal lymph node. (B) A PET-CT scan showed liver metastasis. (C) A bone scan showed femoral metastasis, after 18 months of gefitinib treatment. (D) New lesions occurred after 14 months of osimertinib treatment. (E) Disease progression after crizotinib therapy for one month. (F) Stable disease, after three cycles of pemetrexed plus bevacizumab therapy.

Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords